...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association >Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.
【24h】

Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.

机译：内镜治疗低风险sm1侵袭的食管早期腺癌的疗效，安全性和长期效果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with early-stage mucosal (T1a) esophageal adenocarcinoma (EAC) are increasingly treated by endoscopic resection. EACs limited to the upper third of the submucosa (pT1b sm1) could also be treated by endoscopy. We assessed the efficacy, safety, and long-term effects of endoscopic therapy for these patients.We analyzed data from 66 patients with sm1 low-risk lesions (macroscopically polypoid or flat, with a histologic pattern of sm1 invasion, good-to-moderate differentiation [G1/2], and no invasion into lymph vessels or veins) treated by endoscopic therapy at the HSK Hospital Wiesbaden from 1996 through 2010. The efficacy of endoscopic therapy was assessed on the basis of rates of complete endoluminal remission (CER), metachronous neoplasia, lymph node events, and long-term remission (LTR). Safety was assessed on the basis of rate of complications.Remissions were assessed in 61 of the 66 patients; 53 of the 61 achieved CER (87%). Of patients with small focal neoplasias ≤2 cm, 97% achieved CER (for those with tumors ≥2 cm, 77%; P = .026). Metachronous neoplasias were observed in 10 of 53 patients (19%; 9 of the 10 underwent repeat endoscopic resection). One patient developed a lymph node metastasis (1.9%). Fifty-one patients achieved LTR (84%); 90% of those with focal lesions ≤2 cm achieved LTR after a mean follow-up period of 47 ± 29.1 months (range, 8-120 months). No tumor-associated deaths were observed, and the estimated 5-year survival rate was 84%. The rate of major complications from endoscopic resection was 1.5%, and no patients died.Endoscopic therapy appears to be a good alternative to esophagectomy for patients with pT1b sm1 EAC, on the basis of macroscopic and histologic analyses. The risk of developing lymph node metastases after endoscopic resection for sm1 EAC is lower than the risk of surgery.
机译：早期黏膜（T1a）食管腺癌（EAC）患者越来越多地通过内镜切除术治疗。限于黏膜下层上部（pT1b sm1）的EAC也可以通过内窥镜检查进行治疗。我们评估了内镜治疗对这些患者的疗效，安全性和长期效果。我们分析了66例sm1低风险病变（宏观镜息肉状或扁平状，具有sm1浸润的组织学模式，良好至中度）的数据在1996年至2010年期间，在威斯巴登HSK医院通过内窥镜治疗进行了分化[G1 / 2]分化，并且没有侵入淋巴管或静脉。根据完全管腔内缓解（CER）的比率评估了内窥镜治疗的有效性，异时性肿瘤，淋巴结事件和长期缓解（LTR）。根据并发症发生率评估安全性。对66例患者中的61例进行了缓解评估。 61个国家中有53个达到了CER（87％）。在局灶性小瘤≤2cm的患者中，有97％达到了CER（对于肿瘤≥2cm的患者，有77％; P = .026）。 53例患者中有10例观察到异时性肿瘤（19％; 10例中有9例接受了重复内镜切除术）。一名患者发生了淋巴结转移（1.9％）。 51例患者达到LTR（84％）;在平均随访时间为47±29.1个月（范围8-120个月）后，有90％局灶性病变≤2 cm的患者实现了LTR。没有观察到与肿瘤相关的死亡，估计的5年生存率为84％。内镜切除术的主要并发症发生率为1.5％，无患者死亡。根据宏观和组织学分析，内镜治疗似乎是pT1b sm1 EAC患者食管切除术的替代选择。内镜切除sm1 EAC后发生淋巴结转移的风险低于手术风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号